Sphera Funds Management LTD. Boosts Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Sphera Funds Management LTD. boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 474,103 shares of the biopharmaceutical company's stock after buying an additional 55,000 shares during the quarter. Celldex Therapeutics accounts for approximately 2.2% of Sphera Funds Management LTD.'s holdings, making the stock its 11th biggest position. Sphera Funds Management LTD. owned approximately 0.71% of Celldex Therapeutics worth $11,981,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of CLDX. Rafferty Asset Management LLC grew its stake in shares of Celldex Therapeutics by 67.6% in the fourth quarter. Rafferty Asset Management LLC now owns 152,454 shares of the biopharmaceutical company's stock worth $3,853,000 after acquiring an additional 61,464 shares during the period. Point72 Asset Management L.P. raised its stake in Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock valued at $63,579,000 after buying an additional 847,264 shares during the last quarter. Polar Asset Management Partners Inc. raised its stake in Celldex Therapeutics by 1,318.0% during the 4th quarter. Polar Asset Management Partners Inc. now owns 137,550 shares of the biopharmaceutical company's stock valued at $3,476,000 after buying an additional 127,850 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 18,192 shares of the biopharmaceutical company's stock valued at $460,000 after buying an additional 5,986 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Celldex Therapeutics by 9.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,771 shares of the biopharmaceutical company's stock worth $1,080,000 after buying an additional 3,830 shares during the last quarter.

Celldex Therapeutics Stock Down 5.0%

NASDAQ CLDX traded down $1.03 during trading hours on Wednesday, reaching $19.46. The company's stock had a trading volume of 921,309 shares, compared to its average volume of 893,712. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -7.59 and a beta of 1.39. The firm's 50-day moving average price is $18.91 and its 200-day moving average price is $22.51.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CLDX has been the topic of a number of recent research reports. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley decreased their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, The Goldman Sachs Group dropped their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.